The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells

• Status: Suspended
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating osteonecrosis of femoral head patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sclnow Biotechnology Co., Ltd.

Criteria

Inclusion Criteria:

• Ficat classification is I, IIa, or IIb period

• no obvious improvement or ingravescence by conservative treatment

• patients or their statutory receive human umbilical cord mesenchymal stem cell of their own will, and signed informed consent form

Exclusion Criteria:

• Ficat classification is third or fourth period

• acute, chronic infection patients

• combined with heart, lung, kidney disease, and cannot tolerate operation

• ankylosing spondylitis patient

• acetabular dysplasia patient

• with tumor

• clinical data deficient

• HIV positive

• pregnancy or breast feeding women

• under other therapy that possibly influence MSC security or efficacy